作为一个潜在的目标,PLK4可以增强三阴性乳腺癌的辐射敏感性
Sierra Pellizzari1, Vasudeva Bhat1,2, Harjot Athwal1
1Department of Anatomy and Cell Biology, Western University, N6A 3K7, London, ON, Canada.
Radiation oncology (London, England)
|February 16, 2024
概括
用药物或siRNA抑制波罗样激酶4 (PLK4) 增强了对三阴性乳腺癌 (TNBC) 的放射治疗效果. 这种组合疗法可能涉及中心点过度放大,在TNBC细胞和有机体中显示出显著的抗增殖协同作用.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 放射治疗研究 放射治疗研究
背景情况:
- 三阴性乳腺癌 (TNBC) 呈现放射电阻,阻碍了有效的治疗开发.
- 波罗类激酶4 (PLK4) 抑制,此前已被证明可以增强放射治疗 (RT) 的效果,需要在TNBC中进行进一步的研究.
- 了解PLK4抑制和RT联合的机制对于改善TNBC治疗至关重要.
研究的目的:
- 进一步研究PLK4在增强TNBC中辐射效应中的作用.
- 探索PLK4抑制和RT的联合抗增殖作用背后的机制.
- 评估针对PLK4在TNBC治疗中与RT结合的治疗潜力.
主要方法:
- 用TNBC细胞系和患者衍生器官 (PDO) 的殖民地形成试验来评估细胞增殖.
- 在TNBC细胞系中使用siRNA降低了PLK4的表达.
- 中心放大被评估使用免疫光对抗中心.
主要成果:
- 联合抑制PLK4 (使用CFI-400945或Centrinone B) 或PLK4下调 (通过siRNA) 与RT显著增加了TNBC细胞和PDOs中的抗增殖作用.
- 在用CFI-400945和RT治疗的PDO中证实了抗癌协同作用.
- 鉴定出过度放大中心离子是RT和PLK4抑制的联合抗增殖作用的潜在机制.
结论:
- 在TNBC中,PLK4是增强RT疗效的有希望的治疗标.
- 抑制PLK4和RT的组合显示出显著的协同抗增殖效应.
- 中心管过度放大在观察到的协同作用中起作用,支持进一步的机理学和转化研究.
关键词:
乳腺癌 乳腺癌 乳腺癌CFI-40094545 这是一个很好的方法.中心氨酸 B 氨基酸一个中心体的中心体.组合疗法是一种联合疗法.器官类动物 器官类动物PLK4 PLK4 的时间辐射疗法 辐射疗法三阴性乳腺癌是三阴性乳腺癌.更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K